Abbvie Inc Stock Buy Hold or Sell Recommendation
| ABBV Stock | USD 164.66 0.41 0.25% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding AbbVie Inc is 'Strong Hold'. Macroaxis provides AbbVie buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding AbbVie positions. The advice algorithm takes into account all of AbbVie's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting AbbVie's buy or sell advice are summarized below:
Real Value 164.03 | Target Price 160.21 | Hype Value 164.65 | Market Value 164.66 | Naive Value 162.01 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell AbbVie Inc given historical horizon and risk tolerance towards AbbVie. When Macroaxis issues a 'buy' or 'sell' recommendation for AbbVie Inc, the advice is generated through an automated system that utilizes algorithms and statistical models.
AbbVie |
Execute AbbVie Buy or Sell Advice
The AbbVie recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on AbbVie Inc. Macroaxis does not own or have any residual interests in AbbVie Inc or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute AbbVie's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
AbbVie Trading Alerts and Improvement Suggestions
| The company currently holds 59.38 B in liabilities with Debt to Equity (D/E) ratio of 4.37, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. AbbVie Inc has a current ratio of 0.91, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist AbbVie until it has trouble settling it off, either with new capital or with free cash flow. So, AbbVie's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like AbbVie Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for AbbVie to invest in growth at high rates of return. When we think about AbbVie's use of debt, we should always consider it together with cash and equity. | |
| About 72.0% of AbbVie shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinsons Disease Study |
AbbVie Returns Distribution Density
The distribution of AbbVie's historical returns is an attempt to chart the uncertainty of AbbVie's future price movements. The chart of the probability distribution of AbbVie daily returns describes the distribution of returns around its average expected value. We use AbbVie Inc price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of AbbVie returns is essential to provide solid investment advice for AbbVie.
| Mean Return | 0.05 | Value At Risk | -1.89 | Potential Upside | 1.28 | Standard Deviation | 1.14 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of AbbVie historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
AbbVie Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as AbbVie is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AbbVie Inc backward and forwards among themselves. AbbVie's institutional investor refers to the entity that pools money to purchase AbbVie's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2023-12-31 | 20.9 M | Norges Bank | 2023-12-31 | 20.8 M | Bank Of America Corp | 2023-12-31 | 18.6 M | Legal & General Group Plc | 2023-12-31 | 15.2 M | Ameriprise Financial Inc | 2023-12-31 | 14.2 M | Fmr Inc | 2023-12-31 | 11.1 M | Ubs Group Ag | 2023-12-31 | 10.9 M | Hhg Plc | 2023-12-31 | 9.7 M | T. Rowe Price Associates, Inc. | 2023-12-31 | 9.5 M | Vanguard Group Inc | 2023-12-31 | 160.4 M | Blackrock Inc | 2023-12-31 | 143.2 M |
AbbVie Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (231M) | (40M) | (142M) | (686M) | (417M) | (396.2M) | |
| Change In Cash | 32.6B | (31.5B) | 1.3B | (545M) | 3.6B | 3.8B | |
| Free Cash Flow | 12.8B | 16.8B | 22.0B | 24.2B | 22.1B | 12.0B | |
| Depreciation | 2.0B | 6.5B | 8.5B | 8.5B | 8.7B | 9.1B | |
| Other Non Cash Items | 3.6B | 8.0B | 4.2B | 6.1B | 8.6B | 9.0B | |
| Capital Expenditures | 552M | 798M | 787M | 695M | 777M | 611.5M | |
| Net Income | 7.9B | 4.6B | 11.5B | 11.8B | 4.9B | 6.3B | |
| End Period Cash Flow | 39.9B | 8.4B | 9.7B | 9.2B | 12.8B | 9.8B | |
| Investments | 981M | 114M | (1.4B) | (447M) | (2.0B) | (1.9B) | |
| Change Receivables | (74M) | (929M) | (1.3B) | (1.5B) | (1.3B) | (1.2B) | |
| Net Borrowings | 25.8B | (2.7B) | (8.4B) | (12.4B) | (11.2B) | (10.6B) | |
| Dividends Paid | 6.4B | 7.7B | 9.3B | 10.0B | (10.5B) | (10.0B) | |
| Change To Netincome | 4.8B | 6.4B | 4.0B | 2.6B | 3.0B | 3.4B |
AbbVie Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to AbbVie or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that AbbVie's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a AbbVie stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.0038 | |
β | Beta against NYSE Composite | 0.75 | |
σ | Overall volatility | 1.15 | |
Ir | Information ratio | -0.02 |
AbbVie Volatility Alert
AbbVie Inc has relatively low volatility with skewness of -1.86 and kurtosis of 6.52. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure AbbVie's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact AbbVie's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.AbbVie Implied Volatility
AbbVie's implied volatility exposes the market's sentiment of AbbVie Inc stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if AbbVie's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that AbbVie stock will not fluctuate a lot when AbbVie's options are near their expiration.
AbbVie Fundamentals Vs Peers
Comparing AbbVie's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze AbbVie's direct or indirect competition across all of the common fundamentals between AbbVie and the related equities. This way, we can detect undervalued stocks with similar characteristics as AbbVie or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of AbbVie's fundamental indicators could also be used in its relative valuation, which is a method of valuing AbbVie by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare AbbVie to competition |
| Fundamentals | AbbVie | Peer Average |
| Return On Equity | 0.35 | -0.31 |
| Return On Asset | 0.0807 | -0.14 |
| Profit Margin | 0.09 % | (1.27) % |
| Operating Margin | 0.32 % | (5.51) % |
| Current Valuation | 334.92 B | 16.62 B |
| Shares Outstanding | 1.77 B | 571.82 M |
| Shares Owned By Insiders | 0.10 % | 10.09 % |
| Shares Owned By Institutions | 71.90 % | 39.21 % |
| Number Of Shares Shorted | 13.12 M | 4.71 M |
| Price To Earning | 21.28 X | 28.72 X |
| Price To Book | 27.74 X | 9.51 X |
| Price To Sales | 5.29 X | 11.42 X |
| Revenue | 54.32 B | 9.43 B |
| Gross Profit | 41.53 B | 27.38 B |
| EBITDA | 18.1 B | 3.9 B |
| Net Income | 4.88 B | 570.98 M |
| Cash And Equivalents | 11.88 B | 2.7 B |
| Cash Per Share | 6.72 X | 5.01 X |
| Total Debt | 59.38 B | 5.32 B |
| Debt To Equity | 4.37 % | 48.70 % |
| Current Ratio | 0.93 X | 2.16 X |
| Book Value Per Share | 5.87 X | 1.93 K |
| Cash Flow From Operations | 22.84 B | 971.22 M |
| Short Ratio | 2.04 X | 4.00 X |
| Earnings Per Share | 2.71 X | 3.12 X |
| Price To Earnings To Growth | 0.45 X | 4.89 X |
| Target Price | 184.49 | |
| Number Of Employees | 50 K | 18.84 K |
| Beta | 0.56 | -0.15 |
| Market Capitalization | 287.8 B | 19.03 B |
| Total Asset | 134.71 B | 29.47 B |
| Retained Earnings | (1000 M) | 9.33 B |
| Working Capital | (4.84 B) | 1.48 B |
Note: Acquisition by Edward Rapp of 212 shares of AbbVie at 182.1 subject to Rule 16b-3 [view details]
AbbVie Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as AbbVie . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About AbbVie Buy or Sell Advice
When is the right time to buy or sell AbbVie Inc? Buying financial instruments such as AbbVie Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 19.8B | 22.5B | 30.7B | 32.2B | Total Assets | 146.5B | 138.8B | 134.7B | 81.2B |
Use Investing Ideas to Build Portfolios
In addition to having AbbVie in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Manufacturing Thematic Idea Now
Manufacturing
Companies that provide goods across residential, commercial and industrial construction such as machinery, tools, or lumber production. The Manufacturing theme has 20 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Manufacturing Theme or any other thematic opportunities.
| View All Next | Launch |
Check out AbbVie Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note that the AbbVie Inc information on this page should be used as a complementary analysis to other AbbVie's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for AbbVie Stock analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |
Is AbbVie's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AbbVie. If investors know AbbVie will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AbbVie listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.67) | Dividend Share 5.99 | Earnings Share 2.71 | Revenue Per Share 30.723 | Quarterly Revenue Growth (0.05) |
The market value of AbbVie Inc is measured differently than its book value, which is the value of AbbVie that is recorded on the company's balance sheet. Investors also form their own opinion of AbbVie's value that differs from its market value or its book value, called intrinsic value, which is AbbVie's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AbbVie's market value can be influenced by many factors that don't directly affect AbbVie's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AbbVie's value and its price as these two are different measures arrived at by different means. Investors typically determine if AbbVie is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AbbVie's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.